Open Access
Subscription Access
The cost implications of informed decision-making: a mathematical simulation model of the potential financial effects of a web-based prostate specific antigen decision aid
Abstract
Aim and Objectives: Web-based Prostate Specific Antigen (PSA) decision aids are known to promote informed decision-making. There is also some evidence that informed decision-making can result in reduced uptake of PSA testing, thus reducing subsequent costs related to urological intervention, specifically prostate biopsies. The aim of this study was to assess these potential financial benefits. The objectives were: first, to develop a mathematical simulation model based on data from a randomised controlled trial of a web-based PSA decision aid, Prosdex; second, to examine the effect of changes in PSA testing on prostate biopsy numbers and costs.
Methods: The simulation model was built using an animated simulation package, Simul8, which allowed for the input of parameter data: 1) Setting; 2) Intention to undertake a PSA test, derived from a RCT of a web-based PSA decision aid; 3) Costs related to PSA tests and prostate biopsies.
Results: Total costs varied with changes in the number of PSA tests at a single GP practice, all-Wales and UK level. At the single GP practice level, the effect on costs of changes in PSA testing was minimal. For example, a reduction in PSA testing from 4.6% to 3.6% reduced total costs for the practice by only £1,800. At the UK level, the same reduction in PSA testing lowered costs by approximately £10 million; a relatively small amount of financial resource in the context of a national health budget such as that of the UK National Health Service.
Conclusions: The financial impact of web-based PSA decision aids is minimal. The benefit of using PSA decision aids should be viewed in ethical terms and not in financial terms.References
Evans, R., Edwards, A., Brett, J., Bradburn, M., Watson, E., Austoker, J. & Elwyn, G. (2005). Reduction in uptake of PSA tests following decision aids for patients: systematic review of current aids and their evaluations. Patient Education and Counseling 58, 13-26.
Evans, R., Joseph-Williams, N., Edwards, A., Newcombe, R., Wright, P., Kinnersley, P., Griffiths, J., Jones, M., Williams, J., Grol, R. & Elwyn, G. (2010). Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial. Journal of Medical Internet Research 12 (3) e27.
Catalona, W.J. (1994). Management of cancer of the prostate. New England Journal of Medicine 331, 996-1004.
Selley, S., Donovan, J., Faulkner, A., Coast, J. & Gillat, D. (1997). Diagnosis, management and screening of early localised prostate cancer: a systematic review. Health Technology Assessment 1 (2) 1-96.
Melia, J., Moss, S. & Johns, L. (2004). Rates of prostate specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross sectional study. British Journal of Urology International 94, 51-56.
Williams, N., Hughes, L.J., Turner, E.L., Donovan, J.L., Hamdy, F.C., Neal, D.E., Martin, R.M. & Metcalfe, C. (2010). Prostate-specific antigen testing rates remain low in UK general practice: a cross- sectional study in six English cities. British Journal of Urology International 108, 1402-1408.
Sirovich, B.E., Schwartz, L.M. & Woloshin, S. (2003). Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? Journal of the American Medical Association 289, 1414-1420.
Andriole, G.L., Crawford, E.D., Grubb, R.L. 3rd., Buys, S.S., Chia, D., Church, T.R., et al. (2009). Mortality results from a randomised prostate-cancer screening trial. New England Journal of Medicine 360 (13) 1310-1319.
Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., et al. (2009). Screening and prostate cancer mortality in a randomised European study. New England Journal of Medicine 360 (13) 1320-1328.
Chou, R., Croswell, J.M., Dana, T., Bougatsos, C., Blazina, I., Fu, R., Gleistman, K., Koenig, H.C., Lam, C., Maltz, A., Bruin Rugge, J. & Lin, K. (2011). Screening for prostate cancer: a review of the evidence for the U.S Preventive Services Task Force. Annals of Internal Medicine 155, 762-771.
Moyer, V.A., on behalf of the U.S. Preventive Services Task Force. (2012). Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 157 (2) 120-134.
Watson, E., Jenkins, L., Bukach, C. & Austoker, J. (2002). The PSA test and prostate cancer: information for primary care. Sheffield: NHS Cancer Screening Programmes.
Cardiff University. Prosdex. http://www.prosdex.com/index_content.htm
Marteau, T.M., Dormandy, E. & Michie, S. (2001). A measure of informed choice. Health Expectations 4, 98-108.
Stacey, D., Bennett, C.L., Barry, M.J., Col, N.F., Eden, K.B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Légaré, F. & Thomson, R. (2011). Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews 10:CD001431.
Office for National Statistics. (2010). Population Estimates for UK, England and Wales, Scotland and Northern Ireland, mid 2009. UK Statistics Authority.
Ravindran, A., Phillips, D.T. & Solberg, J.J. (1987). Operations Research: Principles and Practice. 2nd edn. Oxford: John Wiley & Sons.
Imamura, T. & Yasunaga, H. (2008). Economic evaluation of prostate cancer screening with prostate-specific antigen. International Journal of Urology 15, 285-288.
Ekwueme, D.U., Stroud, L.A. & Chen, Y. (2007). Cost analysis screening for diagnosing and staging prostate cancer based on a systematic review of published studies. Preventing Chronic Disease 4, 1-12.
Plymouth Hospitals NHS Trust. (2009). Private healthcare tariff for self-pay patients: 1 October 2009 to 30 September 2010. Available from: http://www.plymouthhospitals.nhs.uk/patients and visitors/privatepatients/Pages/Costs.aspx.
Curtis L. (2008). Unit costs of health and social care 2008. Canterbury: Personal Social Services Research Unit.
Melia, J., Coulson, P., Coleman, D. & Moss, S. (2008). Urological referral of asymptomatic men in general practice in England. British Journal of Cancer 98, 1176-1181.
Department of Health. (2010). NHS reference costs 2008-2009. London: The Stationary Office.
Melia, J., Dearnaley, D., Moss, S., Johns, L., Coulson, P., Moynihan, C., Sweetman, J., Parkinson, M.C., Eeles, R. & Watson, M. (2006). The feasibility and results of a population-based approach to evaluation prostate-specific antigen screening for prostate cancer in men with a reaised familial risk. British Journal of Cancer 94, 499-506.
Department of Health. (2010). Department of Health - Spending Review 2010. London: The Stationary Office.
Feuer, E.J., Etsioni, R., Cronin, K.A. & Mariotto, A. (2004). The use of modelling to understand the impact of screening on U.S mortality: examples from mammography and PSA testing. Statistical Methods in Medical Research 13, 421-442.
Etzioni, R., Gulati, R., Falcon, S. & Penson, D.F. (2008). Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: A surveillance modeling approach. Medical Decision Making 28, 323-330.
Etzioni, R., Gulati, R., Hazelton, W. & Inoue, L. (2008). Modeling and policy development: PSA screening for prostate cancer. Engelberg, Switzerland: Society for Medical Decision Making.
Marshall, T. & Rouse, A. (2008). Resource implications of health benefits of primary prevention strategies for cardiovascular disease in people aged 30-74: mathematical modelling study. British Medical Journal 325, 197-203.
Griffiths, J.D., Lawson, Z.F. & Williams, J.E. (2006). Modelling treatment effects in the HIV/AIDS epidemic. Journal of the Operational Research Society 57, 1413-1424.
DOI: http://dx.doi.org/10.5750/ejpch.v1i1.651
Refbacks
- There are currently no refbacks.